EGFR and lung carcinoma: Applying this approach to patient data, the prediction of ligand-dependent tumor samples based on mRNA data from The Cancer Genome Atlas (TCGA) revealed that colorectal and lung cancer are the two indications most responsive to EGF, which agrees with the approval of EGFR inhibitors in these indications.